Tal Zaks, Exsilio Therapeutics chairman and interim CEO
June 25, 2024 05:00 AM EDTUpdated 06:33 AM
Financing
Startups
Cell/Gene Tx

Can mR­NA be har­nessed for gene in­ser­tion? Mod­er­na's for­mer chief med­ical of­fi­cer has $82M to find out

Lei Lei Wu

News Reporter

Exsilio Ther­a­peu­tics has raised $82 mil­lion in hopes of us­ing mR­NA to sur­mount the lim­i­ta­tions of cur­rent gene ther­a­pies.

mR­NA is a medi­um that the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times